By Steven Reinberg NEW YORK (Reuters Health) Oct 08 –
For patients with prostate cancer who are to undergo radical prostatectomy, 3 months of neoadjuvant hormonal therapy before surgery has no benefit and is not recommended, Scandinavian researchers report.
“Combining two different treatments against cancer is an appealing approach,” lead researcher Dr. Gunnar Aus told Reuters Health. “We tested blocking out testosterone for 3 months prior to radical prostatectomy.”
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!